# Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG

> **NCT03252093** · PHASE2 · TERMINATED · sponsor: **University of Arizona** · enrollment: 6 (actual)

## Conditions studied

- Coronary Artery Bypass Surgery
- Cognitive Impairment

## Interventions

- **DRUG:** Angiotensin-(1-7)
- **DRUG:** Placebo for Angiotensin-(1-7)

## Key facts

- **NCT ID:** NCT03252093
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-20
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-15
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Funding ended
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03252093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03252093, "Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03252093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*